儿科肺高血压:从临床怀疑到管理
Julie Wacker1,2, Maurice Beghetti3,4
1Pediatric Cardiology Unit, Department of Pediatrics, Gynecology, and Obstetrics, Geneva University Hospitals, Rue Willy Donzé 6, 1211 Genève 14, Geneva, Switzerland. julie.wacker@hug.ch.
European journal of pediatrics
|April 9, 2025
概括
儿童肺高血压 (PH) 由于其独特的原因,需要仔细诊断和管理. 新的指导方针完善了分类和风险分层,以改善儿童的治疗结果.
科学领域:
- 儿童心脏病学 儿童心脏病学
- 肺部病理学 肺部病理学
- 临界护理医学 临界护理医学
背景情况:
- 儿童肺高血压 (PH) 与成人PH相比,具有独特的挑战,源于多因素病因和并发症.
- 主要原因包括异常性肺动脉高血压 (PAH),与先天性心脏病 (PAH-CDH) 相关的PAH以及发育性肺部疾病.
- 准确的诊断和分类对于有效的治疗和改善儿童的结果至关重要.
研究的目的:
- 提供有关儿科肺高血压 (PH) 知识的最新摘要.
- 突出第七届世界肺高血压研讨会儿科工作组的重要进展.
- 专注于对分类,风险分层和管理策略的修改.
主要方法:
- 本综述综合了有关儿科PH诊断和管理的当前知识.
- 它结合了第七届肺高血压世界研讨会儿科工作组的发现和建议.
- 重点是更新的分类和风险分层工具.
主要成果:
- 已经扩大了PAH-CDH的分类,超出了简单的分流概念.
- 通过应用25个经过验证的风险因素,提高了儿科PH的风险分层.
- 建议采用以风险为导向的治疗方法,以较低的死亡率为目标,并根据反应进行治疗升级.
结论:
- 经过修订的分类和完善的风险分层提供了改善的方法,以儿科PH.
- 目前的管理依赖于有限的儿科数据,专家意见和成人数据的推断.
- 进一步的研究和儿科专用试验对于推进治疗模式至关重要.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
120
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
120
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
126
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
126
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
107
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
107
Pneumonia IV: Management
271
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
271
Pneumothorax-II
108
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
108
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K


